Page 73 - Read Online

Predicting response to methotrexate, vinblastine, doxorubicin, artifi cial neural networks. Eur J Surg Oncol 2013;39:372-9.
and cisplatin neoadjuvant chemotherapy for bladder cancers 115. Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI.
through genome-wide gene expression profi ling. Clin Cancer Nomograms for bladder cancer. Eur Urol 2008;54:41-53.
Res 2005;11:2625-36. 116. Shariat SF, Karakiewicz PI, Godoy G, Lerner SP. Use of
106. Choi JW, Kim Y, Lee JH, Kim YS. Prognostic signifi cance of nomograms for predictions of outcome in patients with
lactate/proton symporters MCT1, MCT4, and their chaperone advanced bladder cancer. Ther Adv Urol 2009;1:13-26.
CD147 expressions in urothelial carcinoma of the bladder. 117. Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP,
Urology 2014;84:245.e9-15. Palapattu GS, Cote RJ, Sagalowsky AI, Lotan Y. Multiple
107. Tang X, Guo N, Xu L, Gou X, Mi M. CD147/EMMPRIN: biomarkers improve prediction of bladder cancer recurrence
an effective therapeutic target for hepatocellular carcinoma. and mortality in patients undergoing cystectomy. Cancer
J Drug Target 2013;21:224-31. 2008;112:315-25.
108. Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, 118. Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK.
Dinney C, McConkey DJ. Intrinsic basal and luminal Biomarkers in bladder cancer. BJU Int 2010;105:608-13.
subtypes of muscle-invasive bladder cancer. Nat Rev Urol 119. Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H,
2014;11:400-10. Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C,
109. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Montorsi F, Lerner SP, Sagalowsky AI, Cote RJ, Lotan Y.
Bouffi oux C, Denis L, Newling DW, Kurth K. Predicting Combination of multiple molecular markers can improve
recurrence and progression in individual patients with stage prognostication in patients with locally advanced and lymph
Ta T1 bladder cancer using EORTC risk tables: a combined node positive bladder cancer. J Urol 2010;183:68-75.
analysis of 2596 patients from seven EORTC trials. Eur Urol 120. Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P,
2006;49:466-5. Arriaga Y, Bolenz C, Margulis V, Raj GV, Sagalowsky AI,
110. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Shariat SF. Prospective Evaluation of a Molecular Marker
Martinez-Pineiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Panel for Prediction of Recurrence and Cancer-specifi c
Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Survival After Radical Cystectomy. Eur Urol 2013;64:465-71.
Montesinos M, Isorna S, Muntanola P, Gimeno A, Blas M, 121. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ,
Martinez-Pineiro JA. Predicting nonmuscle invasive bladder Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS,
cancer recurrence and progression in patients treated with Kim WY. Intrinsic subtypes of high-grade bladder cancer
bacillus Calmette-Guerin: The CUETO scoring model. J Urol refl ect the hallmarks of breast cancer biology. Proc Natl Acad
2009;182:2195-203. Sci U S A 2014;111:3110-5.
111. Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, 122. Choi W, Porten S, Kim S, Willis D, Plimack ER,
Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J,
Sagalowsky AI, Schoenberg M, Lerner SP. Nomogram Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K,
for predicting disease recurrence after radical cystectomy Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ.
for transitional cell carcinoma of the bladder. J Urol Identifi cation of distinct basal and luminal subtypes of
2006;176:1354-61. muscle-invasive bladder cancer with different sensitivities to
112. Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, frontline chemotherapy. Cancer Cell 2014;25:152-65.
Rogers CG, Vazina A, Bastian PJ, Gupta A, Sagalowsky AI, 123. Brücher BL, Lyman G, van Hillegersberg R, Pollock RE,
Schoenberg M, Lerner SP. Nomograms provide improved Lordick F, Yang HK, Ushijima T, Yeoh KG, Skricka T,
accuracy for predicting survival after radical cystectomy. Clin Polkowski W, Wallner G, Verwaal V, Garofalo A,
Cancer Res 2006;12:6663-76. D’Ugo D, Roviello F, Steinau HU, Wallace TJ, Daumer M,
113. Bassi P, Sacco E, De Marco V, Aragona M, Volpe A. Prognostic Maihle N, Reid TJ 3rd, Ducreux M, Kitagawa Y, Knuth A,
accuracy of an artifi cial neural network in patients undergoing Zilberstein B, Steele SR, Jamall IS. Imagine a world without
radical cystectomy for bladder cancer: a comparison with cancer. BMC Cancer 2014;14:186.
logistic regression analysis. BJU Int 2007;99:1007-12.
114. Buchner A, May M, Burger M, Bolenz C, Herrmann E,
Fritsche HM, Ellinger J, Hofner T, Nuhn P, Gratzke C, How to cite this article: Afonso JP, Freitas R, Lobo F, Morais A,
Brookman-May S, Melchior S, Peter J, Moritz R, Tilki D, Oliveira J, Amaro T, Reis RM, Baltazar FM, Longatto-Filho A, Santos LL.
Urothelial bladder cancer progression: lessons learned from the bench.
Gilfrich C, Roigas J, Zacharias M, Hohenfellner M, J Cancer Metastasis Treat 2015;1:57-66.
Haferkamp A, Trojan L, Wieland WF, Muller SC, Stief CG,
Bastian PJ. Prediction of outcome in patients with urothelial Received: 18-02-2015; Accepted: 05-05-2015.
carcinoma of the bladder following radical cystectomy using Source of Support: Nil, Confl ict of Interest: None declared.

66 Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 2 ¦ July 15, 2015 ¦